Background: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4/-13, key and central drivers of type 2 inflammation in multiple diseases. In the phase 3 LIBERTY ASTHMA VENTURE (VENTURE) study (NCT02528214), dupilumab versus placebo reduced oral corticosteroid (OCS) dose and improved clinical outcomes in patients with OCS-dependent severe asthma. Dupilumab efficacy in patients with varying disease burden (defined by baseline OCS dose) has not been assessed.
Objective: This post hoc analysis of VENTURE evaluated dupilumab efficacy across subgroups defined by baseline OCS dose.
Methods: The OCS dose, proportion no longer needing OCS at week 24, annualized severe exacerbation rate, and least squares mean change from baseline in pre- and post-bronchodilator forced expiratory volume in 1 second at week 24 were evaluated in VENTURE patients with OCS-dependent severe asthma receiving dupilumab 300 mg every 2 weeks versus placebo, categorized by a baseline OCS dose of less than 10 mg/d or 10 or more mg/d.
Results: Dupilumab reduced daily OCS dose from baseline at week 24 in both dose groups. In dupilumab-/placebo-treated patients with a baseline OCS dose of less than 10 mg/d and 10 or more mg/d, 72%/42% and 37%/23% stopped OCS by week 24 (P < .01/P < .05), respectively. Dupilumab significantly reduced the annualized severe exacerbation rate by 71% and 48% (P < .01/P < .05). At week 24, dupilumab improved pre- and post-bronchodilator forced expiratory volume in 1 second in patients in both dose groups.
Conclusions: In patients with OCS-dependent severe asthma receiving lower or higher baseline OCS doses, dupilumab significantly reduced the OCS dose and improved the likelihood of no longer requiring OCS while also reducing exacerbations and improving lung function.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaip.2022.03.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of benralizumab in the Tokyo Asthma Study (TOAST): A real-world prospective interventional trial.
Allergol Int
December 2024
Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan. Electronic address:
Background: Biologics are integral in the management of severe asthma. As the effectiveness of the anti-IL-5 receptor antibody benralizumab in Japan remains elusive, this study aimed to assess its real-world effectiveness in Japanese patients with severe asthma.
Methods: This prospective, interventional, single-arm clinical trial was conducted across ten facilities in Japan between September 2020 and July 2022.
Adequacy of treatment in outpatients with obsessive-compulsive disorder.
Compr Psychiatry
January 2025
Department of Psychiatry, Amsterdam UMC, Amsterdam, The Netherlands; Amsterdam Neuroscience Research Institute, Amsterdam, The Netherlands; Arkin Institute for Mental Health, Amsterdam, The Netherlands.
Objective: To examine whether patients with obsessive-compulsive disorder (OCD) are adequately treated with pharmacotherapy before referral to a specialized center for OCD.
Methods: We performed a retrospective chart review of patients with OCD who were seen for intake at an academic outpatient center in The Netherlands between 2016 and 2023. We collected data on age, gender, illness severity using the Yale-Brown Obsessive-Compulsive Scale, duration of illness, comorbidity and past pharmacotherapy and psychotherapy.
Oral Corticosteroid-Related Healthcare Resource Utilization and Associated Costs in Patients with COPD.
Adv Ther
November 2024
Observational and Pragmatic Research Institute, Singapore, Singapore.
Article Synopsis
- Oral corticosteroids (OCS) are commonly used to manage exacerbations of chronic obstructive pulmonary disease (COPD) but can lead to negative health outcomes that increase healthcare costs and resource use.
- A study analyzed data from the UK Clinical Practice Research Datalink to compare healthcare attendance and costs between COPD patients who used OCS and those who didn’t, focusing on hospital visits and costs.
- Results showed that patients who used OCS had significantly higher healthcare attendance and costs, with the increases correlating positively with the cumulative OCS dose, particularly for primary care consultations and emergency visits.
Real-world mepolizumab treatment in eosinophilic granulomatosis with polyangiitis reduces disease burden in the United States.
Ann Allergy Asthma Immunol
November 2024
Value Evidence and Outcomes, GSK, Upper Providence, Pennsylvania. Electronic address:
Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, chronic inflammatory disease characterized by asthma and small/medium vessel vasculitis. Mepolizumab is approved for use in EGPA disease management alongside oral corticosteroids (OCS), but evidence of its real-world impact is limited.
Objective: To compare real-world treatment patterns and health outcomes, particularly OCS use, EGPA-related hospitalizations/relapses, and asthma exacerbations pre- and post-mepolizumab initiation in US patients with EGPA.
Early Treatment Response to Mepolizumab Predicts Clinical Remission in Severe Eosinophilic Asthma.
J Allergy Clin Immunol Pract
November 2024
Center of Excellence in Treatable Traits, College of Health, Medicine and Wellbeing, University of Newcastle, New Lambton Heights, New South Wales, Australia; Asthma and Breathing Research Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia.
Background: Mepolizumab can induce an early response and clinical remission in people with severe eosinophilic asthma (SEA).
Objective: To find whether early response to mepolizumab (100 mg) could predict future asthma remission and to identify the best predictor of treatment response to mepolizumab for achieving remission.
Methods: The Australian Mepolizumab Registry was used to investigate the early response to mepolizumab at 3 and 6 months and relate this to clinical remission at 12 months.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!